SUTRO BIOPHARMA INC's ticker is STRO and the CUSIP is 869367102. A total of 137 filers reported holding SUTRO BIOPHARMA INC in Q4 2020. The put-call ratio across all filers is 0.60 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $261,291 | -21.7% | 75,300 | +4.9% | 0.00% | – |
| Q2 2023 | $333,917 | +40.6% | 71,810 | +39.7% | 0.00% | – |
| Q1 2023 | $237,468 | -42.8% | 51,400 | 0.0% | 0.00% | – |
| Q4 2022 | $415,312 | +55.5% | 51,400 | +6.9% | 0.00% | – |
| Q3 2022 | $267,000 | +58.9% | 48,100 | +48.9% | 0.00% | – |
| Q2 2022 | $168,000 | -90.1% | 32,300 | -84.3% | 0.00% | -100.0% |
| Q1 2022 | $1,693,000 | -47.2% | 205,924 | -4.5% | 0.00% | 0.0% |
| Q4 2021 | $3,208,000 | -17.0% | 215,566 | +5.3% | 0.00% | -50.0% |
| Q3 2021 | $3,866,000 | +88.4% | 204,677 | +85.5% | 0.00% | +100.0% |
| Q2 2021 | $2,052,000 | +1.5% | 110,357 | +24.2% | 0.00% | 0.0% |
| Q1 2021 | $2,022,000 | +486.1% | 88,824 | +458.6% | 0.00% | – |
| Q4 2020 | $345,000 | +167.4% | 15,900 | +24.2% | 0.00% | – |
| Q3 2020 | $129,000 | +30.3% | 12,800 | 0.0% | 0.00% | – |
| Q2 2020 | $99,000 | – | 12,800 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Samsara BioCapital, LLC | 1,675,579 | $5,814,259 | 1.78% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 5,883,693 | $20,416,415 | 1.10% |
| Kynam Capital Management, LP | 1,552,675 | $5,387,782 | 0.88% |
| Parkman Healthcare Partners LLC | 1,182,168 | $4,102,123 | 0.75% |
| Rubric Capital Management LP | 3,344,810 | $11,606,491 | 0.44% |
| BVF INC/IL | 3,347,946 | $11,617,373 | 0.31% |
| DAFNA Capital Management LLC | 283,079 | $982,284 | 0.31% |
| SECTORAL ASSET MANAGEMENT INC | 432,339 | $1,500,216 | 0.29% |
| Eversept Partners, LP | 769,638 | $2,670,644 | 0.23% |
| Frazier Life Sciences Management, L.P. | 780,000 | $2,706,600 | 0.18% |